1	CAF to the rescue! Potential and challenges of combination antifungal therapy for
2	reducing morbidity and mortality in hospitalized patients with serious fungal
3	infections
4 5	
6	Samantha E. Jacobs ¹ and Vishnu Chaturvedi ^{2,3}
7	
8	¹ Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY,
9	USA
10	² Microbiology and Molecular Biology Laboratories, Department of Pathology,
11	Westchester Medical Center, Valhalla, NY, USA.
12	³ Department of Pathology, Microbiology, and Immunology, New York Medical College,
13	Valhalla, NY, USA.
14	
15	Corresponding author:
16	Samantha Jacobs, MD, MS
17	Icahn School of Medicine at Mount Sinai
18	1 Gustave L. Levy Place, Box 1090
19	New York, NY, USA 10029
20	Phone: 212-241-0824
21	Samantha.jacobs1@mssm.edu
22	ORCID 0000-0002-9770-886X
23	
24	
25	

26 Abstract

27

The global burden of invasive fungal disease (IFD) is substantial and escalating. 28 Combination antifungal therapy (CAF) may improve patient outcomes by reducing 29 development of resistance, improving drug penetration and rate of fungal clearance, 30 and allowing for lower, less toxic antifungal drug doses; yet, increased cost, 31 antagonism, drug-drug interactions, and toxicity are concerns. Clinical practice 32 guidelines recommend antifungal monotherapy, rather than CAF, for most IFDs due to a 33 lack of comparative randomized clinical trials. An examination of the existing body of 34 CAF research should frame new hypotheses and determine priorities for future CAF 35 36 clinical trials. We performed a systematic review of CAF clinical studies for invasive candidiasis, cryptococcosis, invasive aspergillosis, and mucormycosis. Additionally, we 37 summarize findings from animal models of CAF and assess laboratory methods 38 available to evaluate CAF efficacy. Future CAF trials should be prioritized according to 39 animal models showing improved survival and observational clinical data supporting 40 efficacy and safety. 41

43 Introduction

44

45 **Continued dismal outcomes for patients with serious fungal infections**

The global burden of invasive fungal disease (IFD) is substantial, causing approximately 1.5 million deaths per year, and escalating due to a growing population of

immunosuppressed individuals, global health events such as the COVID-19 pandemic,

49 and improvements in molecular diagnostics leading to increased reporting of previously

50 unrecognized or undiagnosed IFD.(1-6)

51 IFDs have considerable economic impact in terms of direct medical costs,

52 productivity loss, and pre-mature deaths.(7) In 2019, the estimated economic burden of

fungal disease in the U.S. was \$11.5 billion, and the mean cost of an inpatient visit

associated with fungal disease diagnosis was more than twice that of the average

55 inpatient stay. Within the healthcare system, IFDs lead to increased length of stay and

56 mortality, and inappropriate empirical antimicrobial therapy.(8-10) Disparate mortality

rates are observed across continents and countries. For example, 30-day all-cause

58 mortality in patients with candidemia is approximately 30% in Europe and the U.S. and

59 60-72% in South Africa and Brazil.(11)

60 **Potential and challenges of combination antifungal therapy**

Given the considerable individual and public health burden of IFDs, emphasis on
research pertaining to antifungal therapeutics is essential. Except for cryptococcal
meningitis, current clinical practice guidelines recommend antifungal monotherapy for
most IFDs; yet, morbidity and mortality remains unacceptably high.(12-19) Combination
antifungal therapy (CAF) is one putative strategy to reduce risk and improve outcomes.
Potential reasons to pursue CAF for IFDs are: (1) To broaden the spectrum of activity

for empirical therapy, (2) to enhance the rate of killing through antifungal synergy/
increased potency, (3) to delay or prevent development of resistance (4) to reduce
antifungal toxicity by using lower drug dosages (5) or to enhance the effectiveness of
older antifungals, and (6) to treat breakthrough infections.(20-23)

CAF may be particularly useful in difficult clinical situations, e.g., infections due to
highly resistant pathogens or biofilm formation, or in tissues with compromised drug
penetration. However, some potentially harmful effects of CAF include reduced fungal
killing (antagonism), drug-drug interactions, increased toxicity, and increased cost.

75 The concept of combining drugs with different mechanisms of action to treat a disease is a longstanding practice supported by rigorous randomized controlled trials 76 (RCTs) for other complex and severe infections including HIV and tuberculosis, as well 77 as oncologic diseases (24-27) Unfortunately, multiple challenges to conducting large-78 scale RCTs exist for patients with IFDs including cost, the significant time to conduct the 79 study, particularly for rare fungi (e.g., Mucorales), and difficulty enrolling medically 80 complex and/or critically ill patients.(28) Due to a lack of RCTs comparing CAF to 81 monotherapy, CAF is reserved for salvage therapy or specific severe disease 82 83 manifestations, e.g., *Candida* endocarditis, in U.S. and international guidelines.(13) To frame new hypotheses and carefully inform clinical trial design, it is important 84 to examine and build upon the existing body of preclinical research and human studies. 85 86 We perform a systematic review of CAF clinical studies for the most prevalent and dangerous fungal pathogens, Candida spp., Cryptococcus neoformans, Aspergillus 87 spp., and the Mucorales. We further summarize findings from experimental research 88

and assess laboratory methods available to evaluate CAF efficacy. Table 1 provides a
"bird's eye view" qualitative summary of the evidence for CAF.

91 Clinical studies of combination antifungal therapy

92 Systematic review methods

93 A systematic review to identify clinical studies of CAF for invasive candidiasis 94 (IC), cryptococcosis, invasive aspergillosis (IA), and invasive mucormycosis was 95 conducted in accordance with the PRISMA guidelines (29) PubMed was searched for 96 English-language publications using the following terms "antifungal combination therapy" or "combination antifungal therapy" and "candida" or "candidiasis", 97 "cryptococcus" or "cryptococcosis" or "cryptococcal", "aspergillus" or "aspergillosis", and 98 "mucorales" or "mucormycosis" or "zygomycetes" or "zygomycosis" (Appendix). We 99 limited our search to manuscripts published between January 1, 2003 (coinciding with 100 the year of U.S. FDA approval of voriconazole) and February 1, 2023. Reference lists 101 from the included studies were additionally screened to identify potentially relevant 102 evidence. We included studies whose primary aim was to evaluate the CAF efficacy for 103 104 proven or probable IFD according to consensus definitions; fungal speciation was not required.(30, 31) Papers were excluded if they were literature reviews or meta-105 analyses, if they did not specify antifungal drug dosages, or if they evaluated 106 107 combinations including non-systemic antifungal agents, e.g., topical or aerosolized formulations, or non-antifungal chemical compounds. 108

109 Systematic review results

110	The PRISMA flowcharts in the Appendix provide a detailed breakdown of the
111	results of the primary search for each of the four IFDs. From 954 publications evaluated,
112	104 articles met the inclusion criteria. These included 21 CAF papers for IC, 17 for
113	cryptococcosis, 45 for IA, and 21 for mucormycosis. Below, we focus our discussion on
114	the findings from randomized trials and large observational studies for each pathogen.
115	Details of each included manuscript, including study design, patient population,
116	antifungal therapy, and patient-related outcomes, are provided in Supplementary Tables
117	1-4.
118	Invasive Candidiasis

Only one RCT of CAF for IC was identified in the systematic review, and the trial was conducted prior to the availability of echinocandins. The trial included 219 nonneutropenic patients who received fluconazole (FLC) 800 mg/d plus placebo vs. FLC plus deoxycholate amphotericin B (dAmB) 0.7 mg/kg/d for candidemia (*C. albicans* in 62%).(32) There was no difference between groups in the primary analysis of time-tofailure, nor in mortality, although overall success rates were higher in the combination vs. monotherapy arm (69% vs. 56%, respectively, P=0.043).

Further clinical data pertaining to CAF for IC was limited to 20 case reports and small case series, most often describing azole-echinocandin or polyene-echinocandin combinations used as salvage therapy. Four case reports and a series of 13 patients with peritoneal dialysis-associated *Candida* peritonitis described favorable outcomes in patients treated with combination dAmB or liposomal AmB (L-AmB) plus flucytosine (5-FC), a regimen still recommended for treatment of deep-seated *Candida* infections, e.g., meningitis and endocarditis, based on limited experimental and clinical data.(13, 33-37)

This combination has shown synergy *in vitro* and is widely used for cryptococcal
meningitis (CM).(38) Moreover, excellent 5-FC levels are achieved in cerebrospinal
fluid (CSF).(39)

136 Cryptococcosis

The systematic review identified 12 RCTs and one prospective, non-randomized trial of induction therapy for CM, all in individuals with HIV/AIDS, as well as 3 retrospective studies and a case report in persons with other immunocompromising conditions. There are no prospective trials in persons without HIV, nor has CAF been evaluated for other manifestations of cryptococcosis, e.g., pulmonary disease.

Several trials established that the combinations of AmB plus 5-FC and AmB plus FLC both achieve improved clinical outcomes as compared to AmB alone.(40-42) However, fungicidal activity, as measured by the rate of reduction in CSF yeast CFU from serial quantitative cultures, is greater with AmB plus 5-FC as compared to AmB plus FLC.(40, 41)

Combination 5-FC and FLC is appealing due to its oral availability and low rates of nephrotoxicity, although prolonged 5-FC is associated with leukopenia.(43) In a pivotal trial in Africa (ACTA) including 721 patients, the all-oral induction regimen of FLC 1200 mg/d plus 5-FC 100 mg/kg/d was non-inferior to dAmB plus FLC or 5-FC for 7 or 14 days for the primary endpoint of 2-week mortality.(44) However, faster CSF clearance was observed with AmB plus 5-FC compared to FLC plus 5-FC.

L-AmB was investigated in a landmark trial, Ambition, in 844 individuals with CM in sub-Saharan Africa. A single 10 mg/kg dose of L-AmB plus 14 days of high-dose FLC

and 5-FC was non-inferior to the WHO-recommended 1-week regimen of dAmB plus 5-155 FC and was associated with fewer adverse events (45) Following the results of the 156 ACTA and Ambition trials, as well as advocacy efforts, generic 5-FC is more widely 157 available at a reduced cost and utilized in routine care.(46) 158 Three-drug combinations of AmB, 5-FC, and FLC have also been studied. While 159 160 the triple therapy had the most potent fungicidal effect in a murine model of CM, it was not more efficacious than AmB plus 5-FC in humans.(40, 47) 161 Other triazole antifungal agents have excellent in vitro activity against 162 *Cryptococcus* spp., and the combination of AmB and voriconazole (VOR) had similar 163 early fungicidal activity as compared to AmB plus 5-FC and AmB plus FLC in a small 164 165 randomized trial.(48, 49) However, VOR, isavuconazole (ISA), and posaconazole (POS) have more side effects and drug-drug interactions, and higher costs than FLC, 166 thus limiting their utility for a disease that is most prevalent in resource-limited settings. 167 168 Invasive Aspergillosis Two randomized trials, 10 observational studies, and 33 case reports/series met 169 170 inclusion criteria in the systematic review of CAF for IA. Prior to widespread use of VOR as standard of care, prospective studies 171 primarily investigated polyene-echinocandin combination. In the randomized, open-172 label Combistrat trial including 30 patients with hematologic malignancy (HM) and IA, 173 those receiving L-AmB 3 mg/kg/d plus caspofungin (CAS) had higher favorable 174 175 response rate (67%) and less acute kidney injury than those receiving high-dose L-AmB 10 mg/kg/d alone (27%, P=0.028 for comparison) for primary therapy.(50) However, L-176

AmB \geq 7.5 mg/kg/d plus CAS combination led to poorer clinical outcomes compared to POS suspension for salvage therapy in a single center compassionate use trial.(51) Further clinical trials with polyene-based combination therapy have not been pursued in the past two decades given a lack of compelling preclinical data, high rates of AmBassociated nephrotoxicity, and studies confirming improved IA-related mortality with VOR.(52, 53)

Observational studies of echinocandin-triazole combination therapy for IA have 183 had inconsistent results depending on the indication and study population. Marr and 184 colleagues compared VOR plus CAS to VOR alone in 47 patients with HM and 185 hematopoietic cell transplant (HCT) recipients with IA who had failed initial therapy with 186 187 AmB. Improved 3-month survival was observed in the combination group compared to monotherapy (HR, 0.42; 95% CI, 0.17–1.1; P=0.048), independent of other variables 188 associated with prognosis.(54) However, in a retrospective study spanning 12 years 189 (1998-2010), VOR plus CAS did not achieve better outcomes than VOR alone, as 190 primary or salvage therapy.(55) In solid organ transplant recipients, compared to a 191 historical cohort receiving L-AmB alone, VOR plus CAS for primary therapy of IA led to 192 similar overall survival at Day 90 (67.5% combination vs. 51% L-AmB monotherapy 193 controls; *P*=0.117). (56) 194

To date, one RCT has evaluated echinocandin-triazole combination for IA. This multicenter, multinational study randomized patients with HM or HCT recipients to VOR plus anidulafungin (AFG) versus VOR alone for primary therapy of proven or probable IA.(57) Amongst 277 patients, there was no difference in 6-week mortality (combination: 19.4%, monotherapy: 27.5%; P=0.087). However, in a post-hoc

200	subgroup analysis of probable IA cases (n=218), 6-week mortality was lower in the
201	combination arm (15.7% vs. 27.3% monotherapy; <i>P</i> =0.037). A limitation of this trial is
202	that statistical power was lower than expected due to higher than expected mortality in
203	both treatment arms.
204	Polyene-triazole combination therapy has received relatively little study in
205	humans given the preclinical data demonstrating variable synergistic interactions.(58)
206	The only comparative data are from a retrospective study in which similar 12-week
207	survival was observed among 49 patients receiving L-AmB 3 mg/kg/d plus VOR or POS
208	vs. L-AmB plus CAS vs. VOR plus echinocandin.(59)
209	Taken together, these single studies have failed to decisively establish a benefit
210	to CAF for IA; however, limitations in study design may preclude definitive
211	determination.
212	Mucormycosis
213	Twenty-one manuscripts, including 6 retrospective studies and 15 case
214	reports/series were included in the systematic review. A 2008 retrospective study by
215	Reed and colleagues was one of the first to suggest a benefit to polyene-echinocandin
216	combination therapy for primary treatment of rhino-orbital-cerebral mucormycosis
217	(ROCM). Amongst 41 patients with ROCM (83% diabetic) between 1994-2006 at two
218	centers, 100% (7 of 7) of patients receiving lipid-complex AmB (ABLC) or L-AmB plus
219	CAS were alive and not in hospital care 30 days after hospital discharge vs. 45%
220	(15/34) of patients on dAmB or a lipid formulation alone (<i>P</i> =0.02).(60) In a multivariate

analysis, only receipt of combination therapy was significantly associated with improved
outcome (OR, 10.9; *P*=0.02).

223 Kyvernitakis and colleagues performed the largest analysis to date in a 224 retrospective study including 106 HM and HCT patients with mucormycosis at a single U.S. cancer center between 1994-2014.(61) For initial therapy, 44% of patients 225 226 received monotherapy (L-AmB 87%, POS 13%) and 56% of patients received CAF (L-AmB + echinocandin, 46%; L-AmB + POS, 27%; triple therapy, 27%), highlighting the 227 228 frequency with which CAF is employed in clinical practice. Using a propensity-score 229 adjusted analysis, they found a similar 6-week survival between patients receiving initial monotherapy vs. combination therapy (56% vs. 60%; P=0.71). 230

An important feature of the abovementioned studies is the relatively long study period spanning over 10 years, which may introduce biases pertaining to changes in fungal diagnostics, supportive care practices, and availability of specific antifungal agents and formulations. An additional limitation to observational studies of IFD treatment is the use of different dosages of antifungal agents, which may affect efficacy and toxicity.

237 Animal studies of combination antifungal therapy

In the absence of large-scale RCTs, animal models of IFDs have several
strengths. They allow for pharmacokinetics of the administered drugs, tissue burden,
and rate of clearance to be assessed. Researchers can integrate host factors and
study a range of doses and dose combinations. Finally, resistant species may be
studied; whereas, enrolling patients with rare and highly resistant fungal pathogen into

clinical trials is quite challenging. With the implementation of ARRIVE (Animal
Research: Reporting In Vivo Experiments) and ARRIVE 2.0 guidelines on the design,
conduct, and reporting of animal studies, it is reasonable to conclude that animal
studies with IFD and CAF will be able to bridge the quality gap with RCTs.(62-64) *Candida spp.*

248 Studies of CAF in experimental models of infections due to *Candida* spp. have 249 yielded mixed results depending on the species, drugs, and methodology. For example, 250 the combination of FLC plus CAS for murine candidemia (*C. albicans*) yielded no 251 change in tissue fungal burden as compared to FLC monotherapy; whereas POS plus 252 CAS led to improved survival compared to either drug alone.(65, 66)

An *in vivo* study by Louie and colleagues further illustrates the complexity of antifungal interactions.(67, 68) In a rabbit model of *Candida albicans* endocarditis and pyelonephritis, both AmB monotherapy and sequential treatment with AmB alone followed by AmB plus FLC rapidly sterilized kidneys and cardiac vegetations. In contrast, simultaneous AmB plus FLC, FLC monotherapy, and FLC followed by AmB were all slower to clear fungi from infected tissues.(68)

Polyene-echinocandin combination is the most frequently studied regimen in the experimental models of IC, particularly due to *C. glabrata*. Compared to monotherapy, AmB plus CAS or L-AmB plus CAS or micafungin (MFG) led to reduced tissue fungal burden in a murine model of systemic infection due to azole-resistant *C. albicans* and *C. glabrata* and in immunosuppressed mice with *C. glabrata* infection.(69-71)

264 Cryptococcus spp.

265	In vivo studies of CAF for cryptococcosis laid the groundwork for subsequent
266	RCTs in humans. In particular, AmB, FLC, and 5-FC, in different dosages and
267	combinations, have been extensively studied in animal models of disseminated disease
268	and meningitis. Schwarz and colleagues demonstrated that AmB plus 5-FC, as
269	compared to monotherapy, led to improved survival and reduced brain tissue fungal
270	burden in murine disseminated cryptococcosis due to 5-FC-susceptible or -resistant C.
271	neoformans.(72) Other studies have found that FLC and AmB, whether given
272	sequentially or combined, lead to greater antifungal activity than AmB alone.(73, 74)
273	The role of high-dose FLC, with or without 5-FC, was further established in murine
274	cryptococcal meningitis.(75)
275	Other triazoles have received lesser attention, either as monotherapy or
276	combination therapy, in experimental models of cryptococcosis.(76)
277	Aspergillus spp.
278	Preclinical studies of azole-echinocandin combinations for IA have garnered
279	significant interest given the favorable safety profile of the latter group. The
280	combinations of POS plus AFG and ISA plus MFG led to improved outcomes in
281	neutropenic models of IA.(77, 78) This synergistic interaction between the
282	echinocandin and the triazole is likely due to simultaneous inhibition of biosynthesis of
283	1,3- β -D-glucan in the fungal cell wall and ergosterol in the cell membrane. However,
284	poorer outcomes observed with VOR plus high-dose AFG suggest that azole-
285	echinocandin interactions may be concentration-dependent.(79)

286	Experimental models of IA treated with azole-polyene combinations have
287	primarily demonstrated antagonism except for CNS disease.(79-82) Again,
288	consideration of the drug mechanism of action may explain these observations.
289	Antifungal azoles deplete the fungal cell membrane of ergosterol and thereby diminish
290	the principal biochemical target of AmB.
291	Polyene-echinocandins combination did not show any benefit for experimental
292	CNS aspergillosis or for invasive pulmonary aspergillosis in immunosuppressed murine
293	models due to chronic granulomatous disease or glucocorticoids.(82-84)
294	Mucorales
295	Azole-polyene combinations for treatment of mucormycosis are frequently used
296	in clinical practice, although preclinical data do not clearly establish a benefit. In
297	neutropenic mice with pulmonary mucormycosis due to <i>R. delemar</i> or <i>M. circinelloides</i> ,
298	L-AmB plus ISA improved survival and reduced tissue fungal burden (lung and brain)
299	compared to either drug alone.(85) However, in murine disseminated mucormycosis
300	due to <i>R. oryzae</i> , L-AmB plus POS did not improve outcomes as compared to L-AmB
301	monotherapy.(86, 87)

Echinocandins do not have *in vitro* activity against Mucorales in standard susceptibility tests, however, some agents of mucormycosis, including *Rhizopus oryzae*, express $(1\rightarrow3)$ - β -D-glucan synthase, which is the target enzyme for echinocandins.(88) Experimental studies of murine mucormycosis due to *R. oryzae* have found improved outcomes when combining lipid formulations of Amb plus echinocandins as compared to either agent alone.(89, 90) The benefit noted with the addition of echinocandins may

be in part due to the class' immunomodulatory effect on the activity of phagocytic
cells.(91) However, no evidence of synergy nor antagonism was noted for the
combination of ISA and MFG in neutropenic mice with pulmonary disease due to *R*. *delemar*.(92)

312 Laboratory methods

There are no standard CLSI or EUCAST methods for *in vitro* testing of antifungal 313 agents in combinations (93). Our literature analysis revealed numerous publications on 314 laboratory testing of antifungal drugs in combinations against yeasts and molds 315 (Supplementary Fig 1). Only a small selection of published studies included details 316 consistent with the inoculum, inclusion of quality control strains, end-point reading, and 317 interpretations of test results per CLSI or EUCAST methods for testing of molds and 318 319 yeasts (94-112). Even publications describing combination testing with standard 320 methods originated from single institutions and the reproducibility of the described method at other institutions remains unknown. The development of a consensus 321 322 method with standardized parameters is imperative for the meaningful testing of antifungal combinations in the clinical laboratory. Towards this end, one of us 323 324 conducted a series of multi-laboratory studies to define the parameters that would allow 325 reproducible antifungal combination testing. We identified a *Candida krusei* QC strain, inoculum size, and 100% inhibition end-point as highly reproducible features for 326 combination testing of *Candida* species and *Aspergillus fumigatus* among six 327 laboratories (113-115). The result interpretations were consistent among laboratories 328 using summation fractional inhibitory concentration indices (Σ FICI) (113, 116). Recent 329 330 re-analysis of the data revealed significant pharmacodynamic interactions with Loewe

additivity-based FICi range of 1–2 FIC and essential agreement with Bliss
independence-based response surface analysis (116). Thus, laboratories now have
access to a standardized method for *in vitro* testing of antifungal agents in
combinations. Further progress is imminent when multi-laboratory studies are
conducted with newer antifungal combinations and with other fungal pathogens.
Similarly, there is an opportunity for device manufacturers to offer commercial
combination panels for wider access to routine laboratory testing.

338 Future prospects

339 Table 2 summarizes ongoing clinical trials of CAF, including those incorporating investigational and non-systemic (e.g., aerosolized) antifungal agents. Promising drugs 340 341 in clinical phases of development with novel mechanisms of action include fosmanogepix, olorofim, and ibrexafungerp.(117) These agents offer hope to expand 342 our antifungal armamentarium, particularly against resistant yeasts and molds, yet will 343 344 face the same environmental and host pressures for emergence of resistance over time. As such, drug development research should investigate these compounds in 345 combinations and even look towards an antifungal "polypill" that might improve patient 346 347 adherence and lessen healthcare costs.(23, 118)

While our review focused on a combinatorial strategy involving antifungal drugs, a particularly novel and emerging area of research is the role of cancer immunotherapies as adjunctive therapy for IFDs. Evidence that fungi induce activation of checkpoint pathways has led to preclinical data demonstrating that blockade of the Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 pathways augments antifungal immunity and improves outcomes.(119) Thus far,

clinical data are limited to case reports for invasive mold diseases.(120, 121) Besides
providing support towards future interventional trials, such investigations of
immunomodulatory therapies to combat IFDs highlight the need to understand the role
of host immune responses in the outcomes of IFDs when designing and interpreting
experimental and clinical studies of CAF.

359 Conclusion

Our systematic review of the literature highlights the paucity of rigorous clinical 360 investigations of CAF for invasive candidiasis and mucormycosis; whereas, multiple 361 362 RCTs establish the superiority of polyene-5-FC CAF for cryptococcosis and one large RCT of azole-echinocandin CAF for IA suggests a benefit in patients with hematologic 363 malignancy and probable IA. Given the challenges to conducting large prospective 364 RCTs for most IFDs, it is reasonable to prioritize future trials of CAF based upon animal 365 models demonstrating improved survival and observational clinical data supporting 366 efficacy and safety. Recent multi-laboratory investigations demonstrated the feasibility 367 of a standardized method of in vitro testing of antifungal combinations for Candida 368 species that should be further investigated with other pathogen and drug combinations. 369

370

371

- 372
- 373

- Author contributions. S.J. and V.C: Conceptualization, systematic literature review,
- writing of original draft, and review and editing.
- 377 Conflict of interest: The authors have no conflicts of interest to declare.
- 378 Funding: None.
- 379 Patient consent statement: Not applicable.

381 **References**

382

383 1. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: Human 384 fungal infections. Science Translational Medicine. 2012;4(165):1-10. 385 2. Seagle EE, Williams SL, Chiller TM. Recent Trends in the Epidemiology of Fungal Infections. 386 Infectious Disease Clinics of North America. 2021;35(2):237-60. 387 Chowdhary A, Gupta N, Wurster S, Kumar R, Mohabir JT, Tatavarthy S, et al. Multimodal analysis 3. 388 of the COVID-19-associated mucormycosis outbreak in Delhi, India indicates the convergence of clinical 389 and environmental risk factors. Mycoses. 2023;66(6):515-26. Steinbrink JM, Hong DK, Bergin SP, Al-Rohil RN, Perfect JR, Maziarz EK. The robust and rapid role 390 4. 391 of molecular testing in precision fungal diagnostics: A case report. Med Mycol Case Rep. 2020;27:77-80. 392 5. Consortium O, Gabaldon T. Recent trends in molecular diagnostics of yeast infections: from PCR 393 to NGS. FEMS Microbiol Rev. 2019;43(5):517-47. 394 6. White PL, Alanio A, Brown L, Cruciani M, Hagen F, Gorton R, et al. An overview of using fungal 395 DNA for the diagnosis of invasive mycoses. Expert Rev Mol Diagn. 2022;22(2):169-84. 396 7. Benedict K, Whitham HK, Jackson BR. Economic Burden of Fungal Diseases in the United States. 397 Open Forum Infectious Diseases. 2022;9(4):6-9. 398 Rayens E, Norris KA. Prevalence and Healthcare Burden of Fungal Infections in the United States, 8. 399 2018. Open Forum Infectious Diseases. 2022;9(1). 400 9. Valerio M, Rodriguez-Gonzalez CG, Munoz P, Caliz B, Sanjurjo M, Bouza E, et al. Evaluation of 401 antifungal use in a tertiary care institution: antifungal stewardship urgently needed. J Antimicrob 402 Chemother. 2014;69(7):1993-9. 403 10. Kara E, Metan G, Bayraktar-Ekincioglu A, Gulmez D, Arikan-Akdagli S, Demirkazik F, et al. 404 Implementation of Pharmacist-Driven Antifungal Stewardship Program in a Tertiary Care Hospital. 405 Antimicrob Agents Chemother. 2021;65(9):e0062921. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of 406 11. 407 invasive candidiasis. Journal of Antimicrobial Chemotherapy. 2018;73:i4-i13. 408 12. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients. Clinical 409 410 Microbiology and Infection. 2012;18(SUPPL.7):19-37. 411 Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical 13. 412 Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2015;62(4):e1-e50. 413 414 14. Patterson TF, Thompson GR, 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice 415 Guidelines for the Diagnosis and Management of Aspergillosis : 2016 Update by the Infectious Diseases 416 Society of America. Clinical Infectious Diseases. 2016;63:1-60. 417 Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, et al. Diagnosis and 15. 418 management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. 419 Clinical Microbiology and Infection. 2018;24:e1-e38. 420 Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global 16. 421 guideline for the diagnosis and management of mucormycosis: an initiative of the European 422 Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and 423 Research Consortium. The Lancet Infectious Diseases. 2019;19(12):e405-e21. 424 Organization WH. Guidelines for diagnosing, preventing and managing cryptococcal disease 17. 425 among adults, adolescents and children living with HIV Geneva2022 [updated 27 June 2022. Available 426 from: https://www.who.int/publications/i/item/9789240052178.

427 Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and 18. 428 Adolescents with HIV 2021 [Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-429 guidelines-adult-and-adolescent-opportunistic-infections/cryptococcosis?view=full. 430 19. Chang CC, Harrison TS, Bicanic TA, Chayakulkeeree M, Sorrell TC, Warris A, et al. Global guideline 431 for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in 432 cooperation with the ASM. Lancet Infect Dis. 2024. 433 Johnson MD, Perfect JR. Use of Antifungal Combination Therapy: Agents, Order, and Timing. 20. 434 Current Fungal Infection Reports. 2010;4(2):87-95. 435 21. Tyers M, Wright GD. Drug combinations: a strategy to extend the life of antibiotics in the 21st 436 century. Nat Rev Microbiol. 2019;17(3):141-55. 437 22. Coates ARM, Hu Y, Holt J, Yeh P. Antibiotic combination therapy against resistant bacterial 438 infections: synergy, rejuvenation and resistance reduction. Expert Rev Anti Infect Ther. 2020;18(1):5-15. 439 23. Wake RM, Allebone-Salt PE, John LLH, Caswall BA, Govender NP, Ben-Ami R, et al. Optimising 440 the Treatment of Invasive Candidiasis – A Case for Combination Therapy. Open Forum Infectious 441 Diseases. 2024. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J 442 24. 443 Med. 1997;336(21):1531-2. 444 25. Collaboration H-C, Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM, et al. The effect of 445 combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 446 2010;24(1):123-37. 447 26. Kerantzas CA, Jacobs WR, Jr. Origins of Combination Therapy for Tuberculosis: Lessons for 448 Future Antimicrobial Development and Application. mBio. 2017;8(2). 449 27. Marshall HT, Djamgoz MBA. Immuno-Oncology: Emerging Targets and Combination Therapies. 450 Front Oncol. 2018;8:315. 451 28. Spellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O, Petrikkos G, et al. Combination 452 therapy for mucormycosis: Why, what, and how? Clinical Infectious Diseases. 2012;54(SUPPL. 1):73-8. 453 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 29. statement: An updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178-89. 454 455 30. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and 456 Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for 457 Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. 458 Clin Infect Dis. 2020;71(6):1367-76. 459 De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions 31. 460 of invasive fungal disease from the European Organization for Research and Treatment of 461 Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious 462 Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813-21. 463 32. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, et al. A randomized and blinded 464 multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as 465 therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 466 2003;36(10):1221-8. 467 33. Abele-Horn M, Kopp A, Sternberg U, Ohly A, Dauber A, Russwurm W, et al. A randomized study 468 comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida 469 infections in intensive care patients. Infection. 1996;24(6):426-32. 470 Pelletier R, Alarie I, Lagace R, Walsh TJ. Emergence of disseminated candidiasis caused by 34. 471 Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol. 472 2005;43(6):559-64.

473 Wong PN, Lo KY, Tong GM, Chan SF, Lo MW, Mak SK, et al. Treatment of fungal peritonitis with a 35. 474 combination of intravenous amphotericin B and oral flucytosine, and delayed catheter replacement in 475 continuous ambulatory peritoneal dialysis. Perit Dial Int. 2008;28(2):155-62. 476 36. Ahuja T, Fong K, Louie E. Combination antifungal therapy for treatment of Candida parapsilosis 477 prosthetic valve endocarditis and utility of T2Candida Panel(R): A case series. IDCases. 2019;15:e00525. 478 37. Wee LE, Wong CSL, Tan AL, Oh HM. Negative cerebrospinal fluid beta-d-glucan levels as an 479 indicator for treatment cessation ahead of biochemical resolution: A case report of Candida glabrata 480 meningitis. Med Mycol Case Rep. 2021;32:47-9. 481 38. O'Brien B, Chaturvedi S, Chaturvedi V. In Vitro Evaluation of Antifungal Drug Combinations 482 against Multidrug-Resistant Candida auris Isolates from New York Outbreak. Antimicrobial Agents and 483 Chemotherapy. 2020;64(4). 484 39. Kethireddy S, Andes D. CNS pharmacokinetics of antifungal agents. Expert Opin Drug Metab 485 Toxicol. 2007;3(4):573-81. 486 40. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, et al. Combination 487 antifungal therapies for HIV-associated cryptococcal meningitis: A randomised trial. Lancet. 488 2004;363(9423):1764-7. 489 Day JN, Chau TTH, Wolbers M, Mai PP, Dung NT, Mai NH, et al. Combination Antifungal Therapy 41. 490 for Cryptococcal Meningitis. New England Journal of Medicine. 2013;368(14):1291-302. 491 42. Pappas PG, Chetchotisakd P, Larsen RA, Manosuthi W, Morris MI, Anekthananon T, et al. A 492 phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-493 associated cryptococcal meningitis. Clin Infect Dis. 2009;48(12):1775-83. 494 Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, et al. Toxicity of 43. 495 amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987;83(2):236-496 42. 497 44. Molloy SF, Kanyama C, Heyderman RS, Loyse A, Kouanfack C, Chanda D, et al. Antifungal 498 Combinations for Treatment of Cryptococcal Meningitis in Africa. N Engl J Med. 2018;378(11):1004-17. 499 Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, et al. Single-Dose Liposomal 45. 500 Amphotericin B Treatment for Cryptococcal Meningitis. N Engl J Med. 2022;386(12):1109-20. 501 46. Hurt WJ, Harrison TS, Molloy SF, Bicanic TA. Combination Therapy for HIV-Associated 502 Cryptococcal Meningitis-A Success Story. J Fungi (Basel). 2021;7(12). Diamond DM, Bauer M, Daniel BE, Leal MA, Johnson D, Williams BK, et al. Amphotericin B 503 47. 504 colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine 505 cryptococcal meningitis. Antimicrob Agents Chemother. 1998;42(3):528-33. 506 Thompson GR, 3rd, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. 48. 507 Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus 508 neoformans. Antimicrob Agents Chemother. 2009;53(1):309-11. 509 49. Loyse A, Wilson D, Meinties G, Jarvis JN, Bicanic T, Bishop L, et al. Comparison of the early 510 fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in 511 combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin 512 Infect Dis. 2012;54(1):121-8. 513 50. Caillot D, Thiébaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, et al. Liposomal 514 amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic 515 malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007;110(12):2740-6. 516 Raad, II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, et al. Novel antifungal agents as 51. 517 salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole 518 compared with high-dose lipid formulations of amphotericin B alone or in combination with 519 caspofungin. Leukemia. 2008;22(3):496-503.

520 52. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following 521 hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin 522 Infect Dis. 2007;44(4):531-40. 523 53. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. 524 Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 525 2002;347(6):408-15. 526 Marr KA, Boeckh M, Carter RA, Hyung WK, Corey L. Combination antifungal therapy for invasive 54. 527 aspergillosis. Clinical Infectious Diseases. 2004;39(6):797-802. 528 55. Raad, II, Zakhem AE, Helou GE, Jiang Y, Kontoyiannis DP, Hachem R. Clinical experience of the 529 use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive 530 aspergillosis in haematological malignancies. Int J Antimicrob Agents. 2015;45(3):283-8. 531 Singh N, Limaye AP, Forrest G, Safdar N, Muñoz P, Pursell K, et al. Combination of voriconazole 56. 532 and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a 533 prospective, multicenter, observational study. Transplantation. 2006;81(3):320-6. 534 Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination 57. 535 antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81-9. 536 58. Kontoyiannis DP, Boktour M, Hanna H, Torres HA, Hachem R, Raad, II. Itraconazole added to a 537 lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive 538 aspergillosis. Cancer. 2005;103(11):2334-7. 539 59. Rojas R, Molina JR, Jarque I, Montes C, Serrano J, Sanz J, et al. Outcome of Antifungal 540 Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the 541 Chosen Combination. Mediterr J Hematol Infect Dis. 2012;4(1):e2012011. 542 60. Reed C, Bryant R, Ibrahim AS, Edwards J, Jr., Filler SG, Goldberg R, et al. Combination polyene-543 caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47(3):364-71. 544 61. Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of 545 combination treatment does not impact survival of 106 patients with haematologic malignancies and 546 mucormycosis: a propensity score analysis. Clinical Microbiology and Infection. 2016;22(9):811.e1-.e8. 547 62. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research 548 reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412. 549 63. Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, et al. Reporting animal 550 research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 2020;18(7):e3000411. 551 Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 64. 552 2.0: Updated guidelines for reporting animal research. J Cereb Blood Flow Metab. 2020;40(9):1769-77. 553 Graybill JR, Bocanegra R, Najvar LK, Hernandez S, Larsen RA. Addition of caspofungin to 65. 554 fluconazole does not improve outcome in murine candidiasis. Antimicrob Agents Chemother. 555 2003;47(7):2373-5. 556 Chen YL, Lehman VN, Averette AF, Perfect JR, Heitman J. Posaconazole exhibits in vitro and in 66. 557 vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. PLoS One. 558 2013;8(3):e57672. 559 Fioriti S, Brescini L, Pallotta F, Canovari B, Morroni G, Barchiesi F. Antifungal Combinations 67. 560 against Candida Species: From Bench to Bedside. J Fungi (Basel). 2022;8(10). 561 68. Louie A, Kaw P, Banerjee P, Liu W, Chen G, Miller MH. Impact of the order of initiation of 562 fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis. Antimicrob Agents Chemother. 563 564 2001;45(2):485-94. 565 Hossain MA, Reves GH, Long LA, Mukherjee PK, Ghannoum MA. Efficacy of caspofungin 69. 566 combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother. 567 2003;51(6):1427-9.

568 Barchiesi F, Spreghini E, Fothergill AW, Arzeni D, Greganti G, Giannini D, et al. Caspofungin in 70. 569 combination with amphotericin B against Candida glabrata. Antimicrob Agents Chemother. 570 2005;49(6):2546-9. 571 71. Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT. Treatment of Candida glabrata infection in 572 immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or 573 micafungin. Antimicrob Agents Chemother. 2005;49(12):4895-902. 574 Schwarz P, Dromer F, Lortholary O, Dannaoui E. Efficacy of amphotericin B in combination with 72. 575 flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans 576 during disseminated murine cryptococcosis. Antimicrob Agents Chemother. 2006;50(1):113-20. 577 73. Larsen RA, Bauer M, Thomas AM, Graybill JR. Amphotericin B and fluconazole, a potent 578 combination therapy for cryptococcal meningitis. Antimicrob Agents Chemother. 2004;48(3):985-91. 579 74. Barchiesi F, Schimizzi AM, Caselli F, Novelli A, Fallani S, Giannini D, et al. Interactions between 580 triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother. 581 2000;44(9):2435-41. 582 Hossain MA, Mukherjee PK, Reyes G, Long L, Ghannoum MA. Effects of fluconazole singly and in 75. 583 combination with 5-fluorocytosine or amphotericin B in the treatment of cryptococcal 584 meningoencephalitis in an intracranial murine model. J Chemother. 2002;14(4):351-60. 585 76. Silva EG, Paula CR, Dias AL, Chang MR, Ruiz Lda S, Gambale V, et al. Combination efficacy of 586 voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by 587 fluconazole-resistant Cryptococcus neoformans. Mycopathologia. 2011;171(4):261-6. 588 Martin-Vicente A, Capilla J, Guarro J. Synergistic effect of anidulafungin combined with 77. 589 posaconazole in experimental aspergillosis. Med Mycol. 2017;55(4):457-60. 590 78. Petraitis V, Petraitiene R, McCarthy MW, Kovanda LL, Zaw MH, Hussain K, et al. Combination 591 Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary 592 Aspergillosis. Antimicrob Agents Chemother. 2017;61(9). 593 79. Petraitis V, Petraitiene R, Hope WW, Meletiadis J, Mickiene D, Hughes JE, et al. Combination 594 Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the 595 Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss 596 Independence Drug Interaction Analysis. Antimicrobial agents and chemotherapy. 2009;53(6):2382-91. 597 80. Schaffner A, Frick PG. The effect of ketoconazole on amphotericin B in a model of disseminated 598 aspergillosis. J Infect Dis. 1985;151(5):902-10. 599 Martin-Vicente A, Capilla J, Guarro J. In Vivo Synergy of Amphotericin B plus Posaconazole in 81. 600 Murine Aspergillosis. Antimicrob Agents Chemother. 2016;60(1):296-300. 601 82. Clemons KV, Parmar R, Martinez M, Stevens DA. Efficacy of Abelcet alone, or in combination 602 therapy, against experimental central nervous system aspergillosis. J Antimicrob Chemother. 603 2006;58(2):466-9. 604 83. Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against experimental 605 pulmonary aspergillosis. Med Mycol. 2006;44(1):69-73. 606 Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ, et al. Effect of amphotericin B 84. 607 and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis 608 in the p47phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother. 609 2006;50(2):422-7. 610 85. Gebremariam T, Gu Y, Singh S, Kitt TM, Ibrahim AS. Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis. J Antimicrob 611 612 Chemother. 2021;76(10):2636-9. 613 Ibrahim AS, Gebremariam T, Schwartz JA, Edwards JE, Jr., Spellberg B. Posaconazole mono- or 86. 614 combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother. 615 2009;53(2):772-5.

616 87. Rodríguez MM, Serena C, Mariné M, Pastor FJ, Guarro J. Posaconazole combined with 617 amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. 618 Antimicrob Agents Chemother. 2008;52(10):3786-8. 619 88. Ibrahim AS, Bowman JC, Avanessian V, Brown K, Spellberg B, Edwards JE, Jr., et al. Caspofungin 620 inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative 621 PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. 622 Antimicrob Agents Chemother. 2005;49(2):721-7. 623 Spellberg B, Fu Y, Edwards JE, Jr., Ibrahim AS. Combination therapy with amphotericin B lipid 89. 624 complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob 625 Agents Chemother. 2005;49(2):830-2. 626 90. Ibrahim AS, Gebremariam T, Fu Y, Edwards JE, Jr., Spellberg B. Combination echinocandin-627 polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52(4):1556-8. 628 91. Lamaris GA, Lewis RE, Chamilos G, May GS, Safdar A, Walsh TJ, et al. Caspofungin-mediated 629 beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against 630 Aspergillus and non-Aspergillus hyphae. J Infect Dis. 2008;198(2):186-92. 631 Gebremariam T, Wiederhold NP, Alqarihi A, Uppuluri P, Azie N, Edwards JE, Jr., et al. 92. 632 Monotherapy or combination therapy of isavuconazole and micafungin for treating murine 633 mucormycosis. J Antimicrob Chemother. 2017;72(2):462-6. 634 93. Bidaud A-L, Schwarz P, Herbreteau G, Dannaoui E. Techniques for the assessment of in vitro and 635 in vivo antifungal combinations. Journal of Fungi. 2021;7(2):113. 636 Meletiadis J, Beredaki MI, Elefanti A, Pournaras S, Muller A. In Vitro-In Vivo Correlation of 94. 637 Posaconazole-Amphotericin B Combination against Candida albicans: In Vitro Interacting Concentrations 638 Are Associated with In Vivo Free Drug Levels. J Fungi (Basel). 2023;9(4). 639 95. John LL, Thomson DD, Bicanic T, Hoenigl M, Brown AJ, Harrison TS, et al. Heightened efficacy of 640 anidulafungin when used in combination with manogepix or 5-flucytosine against Candida auris in vitro. 641 Antimicrob Agents Ch. 2023:e01645-22. 642 96. O'Brien B, Chaturvedi S, Chaturvedi V. In vitro evaluation of antifungal drug combinations against multidrug-resistant Candida auris isolates from New York outbreak. Antimicrobial agents and 643 644 chemotherapy. 2020;64(4):10.1128/aac. 02195-19. 645 97. Shi C, Liu CL, Liu JY, Wang Y, Li J, Xiang MJ. Anti-Candida Activity of New Azole Derivatives Alone 646 and in Combination with Fluconazole. Mycopathologia. 2015;180(3-4):203-7. 647 Planche V, Ducroz S, Alanio A, Bougnoux ME, Lortholary O, Dannaoui E. In vitro combination of 98. 648 anidulafungin and voriconazole against intrinsically azole-susceptible and -resistant Aspergillus spp. 649 Antimicrob Agents Chemother. 2012;56(8):4500-3. 650 99. Venturini TP, Rossato L, Spader TB, Tronco-Alves GR, Azevedo MI, Weiler CB, et al. In vitro 651 synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against 652 Fusarium spp. Diagn Microbiol Infect Dis. 2011;71(2):126-30. 100. 653 Ben-Ami R, Lewis RE, Kontoyiannis DP. In vitro interactions among echinocandins against 654 Aspergillus fumigatus: lack of concordance among methods. Medical mycology. 2011;49(3):285-8. 655 Cuenca-Estrella M, Alastruey-Izquierdo A, Alcazar-Fuoli L, Bernal-Martinez L, Gomez-Lopez A, 101. 656 Buitrago MJ, et al. In vitro activities of 35 double combinations of antifungal agents against 657 Scedosporium apiospermum and Scedosporium prolificans. Antimicrob Agents Ch. 2008;52(3):1136-9. 658 102. Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. Comparative in vitro activities of 659 posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and 660 synergy testing for Rhizopus. Sabouraudia. 2008;46(6):567-73. 661 Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, Mellado E, Garcia-Effron G, Rodriguez-Tudela 103. 662 JL. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen 663 Scopulariopsis brevicaulis. Antimicrob Agents Ch. 2006;50(6):2248-50.

Philip A, Odabasi Z, Rodriguez J, Paetznick VL, Chen E, Rex JH, et al. In vitro synergy testing of
anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium
spp. Antimicrob Agents Ch. 2005;49(8):3572-4.

- Lewis RE, Kontoyiannis DP. Micafungin in combination with voriconazole in Aspergillus species: a
 pharmacodynamic approach for detection of combined antifungal activity in vitro. J Antimicrob
 Chemoth. 2005;56(5):887-92.
- 670 106. Cuenca-Estrella M, Gomez-Lopez A, Garcia-Effron G, Alcazar-Fuoli L, Mellado E, Buitrago MJ, et
- al. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-
- resistant clinical isolates of Aspergillus fumigatus. Antimicrob Agents Ch. 2005;49(3):1232-5.
- 573 107. Srimuang S, Prariyachatigul C, Chaiprasert A, Rungsipanuratn W, Tanphaichitra D. Antifungal
 674 drug combinations for Cryptococcus neoformans and Prototheca spp. J Med Assoc Thai. 2000;83(1):5760.
- 676 108. Barchiesi F, Di Francesco LF, Compagnucci P, Arzeni D, Giacometti A, Scalise G. In-vitro
- interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates ofCandida albicans. J Antimicrob Chemother. 1998;41(1):59-65.
- 679109.Hanson LH, Stevens DA. Comparison of antifungal activity of amphotericin B deoxycholate680suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob Agents
- 681 Chemother. 1992;36(2):486-8.
- 682 110. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational
 683 Supplement. CLSI document M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.
 684 2015.
- 685 111. CLSI. Performance standards for antifungal susceptibility testing of yeasts: CLSI supplement
 686 M60. Wayne, PA, USA: CLSI; 2017.
- 687 112. Meletiadis J, Pournaras S, Roilides E, Walsh TJ. Defining fractional inhibitory concentration index
- cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation
 analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus
 fumigatus. Antimicrob Agents Chemother. 2010;54(2):602-9.
- Ren P, Luo M, Lin S, Ghannoum MA, Isham N, Diekema DJ, et al. Multilaboratory testing of
 antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent
 inhibition as the endpoint. Antimicrobial Agents and Chemotherapy. 2015;59(3):1759-66.
- 694 114. Chaturvedi V, Ramani R, Andes D, Diekema DJ, Pfaller MA, Ghannoum MA, et al. Multilaboratory
 695 testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida
 696 parapsilosis. Antimicrob Agents Chemother. 2011;55(4):1543-8.
- 697 115. Chaturvedi V, Ramani R, Ghannoum MA, Killian SB, Holliday N, Knapp C, et al. Multilaboratory
 698 testing of antifungal combinations against a quality control isolate of Candida krusei. Antimicrob Agents
 699 Chemother. 2008;52(4):1500-2.
- Meletiadis J, Andes DR, Lockhart SR, Ghannoum MA, Knapp CC, Ostrosky-Zeichner L, et al.
 Multicenter Collaborative Study of the Interaction of Antifungal Combinations against Candida Spp. by
- Loewe Additivity and Bliss Independence-Based Response Surface Analysis. J Fungi (Basel). 2022;8(9).
- 117. Jacobs SE, Zagaliotis P, Walsh TJ. Novel antifungal agents in clinical trials. F1000Res.
 2021;10:507.
- 118. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill
 Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-77.
- Wurster S, Watowich SS, Kontoyiannis DP. Checkpoint inhibitors as immunotherapy for fungal
 infections: Promises, challenges, and unanswered questions. Front Immunol. 2022;13:1018202.
- 709 120. Serris A, Ouedrani A, Uhel F, Gazzano M, Bedarida V, Rouzaud C, et al. Case Report: Immune
- 710 Checkpoint Blockade Plus Interferon-Gamma Add-On Antifungal Therapy in the Treatment of Refractory
- 711 Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis. Front Immunol. 2022;13:900522.

- 712 121. Grimaldi D, Pradier O, Hotchkiss RS, Vincent JL. Nivolumab plus interferon-gamma in the
- treatment of intractable mucormycosis. Lancet Infect Dis. 2017;17(1):18.

714

Table 1. Bird's eye view: Summary of clinical and experimental evidence supporting combination antifungal therapy for the most prevalent and dangerous fungal pathogens

RCT of FLC vs. FLC + dAmB published in 2003 trended toward red success in combination arm mental models of systemic <i>C. albicans</i> and <i>C. glabrata</i> infection ily support polyene-echinocandin combination y of experimental and clinical data investigating CAF for azole- and candin-resistant <i>Candida</i> spp. and <i>C. auris</i> respective trials incorporating echinocandins for CAF have been cted e large RCTs in HIV/AIDS-associated cryptococcal meningitis restrate that induction CAF with AmB + 5-FC leads to improved piologic and clinical outcomes compared to monotherapy
ily support polyene-echinocandin combination y of experimental and clinical data investigating CAF for azole- and candin-resistant <i>Candida</i> spp. and <i>C. auris</i> spective trials incorporating echinocandins for CAF have been cted e large RCTs in HIV/AIDS-associated cryptococcal meningitis istrate that induction CAF with AmB + 5-FC leads to improved iologic and clinical outcomes compared to monotherapy
candin-resistant <i>Candida</i> spp. and <i>C. auris</i> spective trials incorporating echinocandins for CAF have been cted e large RCTs in HIV/AIDS-associated cryptococcal meningitis strate that induction CAF with AmB + 5-FC leads to improved iologic and clinical outcomes compared to monotherapy
e large RCTs in HIV/AIDS-associated cryptococcal meningitis astrate that induction CAF with AmB + 5-FC leads to improved iologic and clinical outcomes compared to monotherapy
istrate that induction CAF with AmB + 5-FC leads to improved iologic and clinical outcomes compared to monotherapy
doca L Amp 10 malka + 14 dove x 5 50 and 510 pow first line
-dose L-AmB 10 mg/kg + 14 days x 5-FC and FLC now first-line en in resource-limited settings
spective trials in non-HIV/AIDS immunocompromised hosts, nor in NS manifestations of cryptococcosis
large multination RCT of VOR + AFG vs. VOR alone trended toward red 6-week mortality in HM patients with IA (P=0.087)
echinocandin combinations strongly supported by experimental s of IA
mental studies of azole-polyene combinations primarily demonstrate onism; very limited clinical data show no difference compared to AmB
ective clinical data to inform CAF for azole-resistant <i>Aspergillus</i> spp. king
results of azole-polyene CAF from experimental data; polyene- candin CAF <i>in vivo</i> synergy may be species-specific
spective trials of CAF exist; largest retrospective analysis of CAF
,

AmB, liposomal amphotericin B; POS, posaconazole; RCT, randomized clinical trial; VOR,

721 voriconazole

Table 2: Ongoing clinical trials of combination antifungal therapy for invasive fungal diseases

ClinicalTrials.gov ID	Phase	Sponsor	Disease	Treatment arms	Primary endpoint	Status
NCT03672292 Scynergia Trial	2	Scynexis, Inc., USA	Invasive pulmonary aspergillosis	Arm 1: Ibrexafungerp + voriconazole Arm 2: voriconazole+ placebo	Adverse events, death through study completion	Completed, no results posted
NCT05238116 OPERA-T Trial	3	Pulmocide Ltd, UK	Refractory invasive pulmonary aspergillosis	Arm 1: Opelconazole (inh) + systemic antifungal therapy Arm 2: Placebo (inh) + systemic antifungal therapy	Complete or partial overall response up to 12 weeks	Recruiting
NCT05541107 EnACT3 Trial	3	Matinas BioPharma Nanotechnologies, Inc., USA	Cryptococcal meningitis	Arm 1: cAMB + flucytosine induction followed by cAMB + fluconazole consolidation Arm 2: cAMB + 5 flucytosine induction followed by SOC consolidation Arm 3: SOC induction followed by SOC consolidation	All-cause mortality at 2 weeks	Not yet recruiting
NCT04502381	2	Postgraduate Institute of Medical Education and Research, India		Arm 1: Inh deoxycholate AmB + IV liposomal AmB Arm 2: IV liposomal AmB	Overall response (clinical and radiological) at 6 weeks	Completed, no results posted

723 cAmB, encochleated amphotericin B; Inh, inhaled; SOC, standard of care